UK must maintain leadership in stem cell technology
21 January 2009
Excalibur, an international investment house specialising in medical
sciences, says that the UK must 'maintain its momentum' to deliver
pioneering stem cell treatments if it is to remain at the forefront of
Professor Sir Christopher Evans, founder and chairman of Excalibur,
welcomed the announcement that ReNeuron plc has received approval from
the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to
commence a first-in-man clinical trial for the treatment of patients who
have been left disabled by an ischaemic stroke.
Sir Christopher said: "We founded ReNeuron with Dr John Sinden and
have invested in the company every step of the way for the last 10
years. We are proud the company has now reached this important milestone
in its development of cell therapy treatment for stroke. There have been
many scientific and financial hurdles to overcome during these years but
we were determined to see this through.
"It is absolutely essential that we in the UK maintain our momentum
in stem cell development and our belief in our ability to deliver these
potentially revolutionary treatments. Too often in this country there is
a tendency to focus on potentially negative outcomes but today's
announcement is extremely important news for victims of stroke. At the
end of the day lives — and the future of medicine in this area — could
be transformed by this science."
Bookmark this page